medigraphic.com
ISSN 0035-0052 (Print)

2007, Number 4

<< Back Next >>

Rev Mex Pediatr 2007; 74 (4)

Clinical experience using surfactant in neonates born below 1,500 g

López-Anacleto GC, Bautista-Soto C, Anguiano-Reséndiz M, Delgado-Díaz S, Ortiz-Ortiz R, Martínez-Juárez RC

Language: Spanish
References: 19
Page: 147-151
PDF size: 134.41 Kb.


ABSTRACT

Objective. To review our experience obtained using exogenous surfactant (ES) in new born infants with breathing distress syndrome (BDS).
Material and methods. Retrospective study in 54 neonates with BDS and a body weight below 1,500 g, treated with ES. Information was obtained about the clinical evolution and in relation to adverse effects of the treatment.
Results. The premature babies went from 24 to 34 weeks of gestational age. In 15% of them the ES the surfactant was used as prophyilactic treatment and in 85% was used rescue doses. The BDS was related to pneumothorax (12%), pneumonia (52%), lung hemorrhages (29%), broncopulmonary displasy (28%) and intraventricular hemorrhages (HIV) 24%. The mortality rate of infants below 1,500 grams of body weight during the period of study was 9.8%.
Conclusions. The treatment of BDS infants with ES has been contributing to the diminished the mortality rate in these premature infants.


REFERENCES

  1. Avery ME, Mead J. Surface properties in relation to atelectasias and hyaline membrane disease. Am J Dis Child 1959; 97: 517-23.

  2. Avery ME. Surfactant deficiency in hyaline membrane disease: the story of discovery. Am J Respir Crit Care Med 2000; 161: 1074-5.

  3. Jobe AH. The respiratory system. In: Fanaroff AA, Martin RJ. Neonatal perinatal medicine. 5° ed. Philadelphia: Mosby Yearbook, 1992: 354-9.

  4. Jobe AH. Why surfactant works for respiratory stress syndrome. Neonatol Reviews 2005; 7: 125-8.

  5. Lacaze MT. Expanded use of surfactante therapy in newborn. Clin Perinatol 2007; 34: 79-89.

  6. Jobe AH. Biology of surfactant. Clin Perinatol 2001; 28: 655-69.

  7. Kallapur MS. The surfactants. Am J Perinatol 2000; 17: 335-43.

  8. Blanco O. Propiedades antiinflamatorias del surfactante pulmonar y su aplicación en la clínica. Biotec Aplicada 2004; 21: 70-6.

  9. Cordero GG. Tendencias actuales en el manejo del síndrome de dificultad respiratoria en el Instituto Nacional de Perinatología. Rev Perinatol 2006; 21: 2-7.

  10. Burckhart AE, Towers CV, Rumney PJ, Lewis DF. Neonatal outcome when delivery follows a borderline inmature lecithin to sphingomyelina ratio. J Perinatol 2000; 20: 57-60.

  11. Foix-L’Helias L, Baud O, Leclen R, Kaminski M, Lacaze-Masmonteil T. Benefit of antenatal glucocorticoids according to the cause of very premature brith. Arch Dis Child Fetal Neonatal Ed 2005; 90: F46-8.

  12. Crowley P. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 1995; 173(1): 322-35.

  13. Malloy MH, Freman DH. Respiratory distress syndrome mortality in the United States, 1987 to 1995. J Perinatol 2000; 20: 414-20.

  14. Jobe AH. Mechanisms to explain surfactant responses. Biol Neonate 2006; 89: 298-302.

  15. MacDonald CL, Sean BA. An update on the use of surfactant in neonates. Curr Pediatr 2004; 14: 284-9.

  16. Suresh GK, Soil RF. Lung surfactants for neonatal respiratory distress syndrome animal-derived or synthetic agents? Pediatr Drugs 2002; 4: 485-492.

  17. Clements JA, Avery ME. Lung surfactant and neonatal respiratory distress syndrome. Am J Resp Crit Care Med 1998.

  18. trials. J Perinatol 2005; 25: S40-4.

  19. Soll RF, Morley C. Profilactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews CD000510. 2001.




2020     |     www.medigraphic.com